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A B S T R A C T
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex upper airway disease affecting up to 11% of the
population of Western Europe. In these western countries, 85% of the CRSwNP disease reveals a type 2 inﬂam-
matory pattern. In the last 15 years, several randomized double-blind studies on monoclonal antibodies in
CRSwNP were performed. These studies demonstrated for the ﬁrst time that biologics targeting type 2 immune
reactions might be successful in nasal polyps. The target proteins, interleukin (IL)-4, IL-5, IL-13, and IgE were
previously identiﬁed as key mediators in studies using nasal polyp tissues to measure and to interact in ex-vivo
settings. No biomarkers have been identiﬁed to predict response to a speciﬁc biologic or to monitor treatment
success. These studies were characterized by small numbers of patients and heterogeneous populations. They did,
however, pave the way for currently performed and analyzed phase 3 studies, which will possibly lead to the
registration of the ﬁrst biologic drug with the indication CRSwNP. The studies already provide indications on the
effects to be expected from those biologics; the results of phase-3 studies in larger populations will be decisive for
the indications, patient selection, and ﬁnally the stopping rules for those drugs in subjects with severe nasal
polyps, in whom the current standard of care including topical and oral glucocorticosteroids, antibiotics and
surgical procedures failed to control the disease. We may expect that those biologics will open new perspectives
for those patients with severe polyposis with, but also independent of asthma, allowing to avoid the possible
adverse events resulting from systemic glucocorticosteroids and surgery.
Background
Proof-of-concept trials with anti-interleukin (IL)5 (reslizumab,
mepolizumab), anti-IgE (omalizumab), and anti-IL4 receptor alpha
(dupilumab) in chronic rhinosinusitis with nasal polyps (CRSwNPs)
recently revealed an innovative therapeutic potential.1 These biologicals
target speciﬁc molecules and immune cells or inﬂammatory pathways
associated with a speciﬁc pathomechanism, such as IL-5 orchestrating the
survival of eosinophils,2 or IL-4 and IL-13 regulating the formation of
IgE3 and the chemotaxis of eosinophils,4,5 among other effects. Beneﬁcial
treatment effects such as signiﬁcantly reduced symptoms and polyp
scores, resulting in an increased quality of life, have been seen in patients
with severe CRSwNPs, with and without comorbid asthma. Effects of
different magnitude and patterns have been illustrated for the different
biologics, and they will be discussed here.
Chronic rhinosinusitis (CRS) affects more than 10% of the population
in western countries, 12% in the United States;6 11% in the Europe7 and
8–11% in Asia.8,9 Chronic rhinosinusitis with nasal polyps (CRSwNP), a
phenotype of CRS, is a persistent inﬂammatory disease of the paranasal
sinuses, and in 10%–70% accompanied by asthma.10 CRSwNP is
affecting more than 4% of the population, with about a third of patients
not controlled with the current standard of care approach, consisting of
topical and systemic glucocorticosteroids (GCS), antibiotics and (often
repeated) sinus surgery.11 Within 18 months of an endoscopic sinus
surgery (ESS), 40% of the CRSwNP patients have been reported with
polyp recurrence of disease in three US university clinics.11 The
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physicians then have to deal with the recurrences, and only can offer
nasal or oral GCS or repeated surgery, with the likelihood of further
recurrence. Based on cluster analysis of the inﬂammatory mechanisms in
patients with CRS, our group for the ﬁrst time published an approach to
endotype CRS, differentiating the disease purely based on biomarkers.10
The type 2 clusters largely correlated with phenotypes and furthermore
were associated with disease severity, asthma comorbidity and recur-
rence of diseases. These biomarkers form the targets for innovative
therapeutic approaches such as monoclonal antibodies. The ﬁrst publi-
cation is already dated from 2006,12 and in the meantime our group has
worked with biologics to treat CRSwNP for 12 years. The aim of this
review is to summarize the current studies on biologics for nasal polyps,
compare the study designs and results of the published data, and further
discuss the feasibility of using the biologics as an innovative way to treat
CRSwNPs.
Comparison of biotherapeutics studied in nasal polyposis
Four studies involving 3 monoclonal antibodies (mepolizumab,
omalizumab, dupilumab) were included in the comparison. These 3
monoclonal antibodies are blocking different relevant key pathogenic
molecules: mepolizumab targets IL-5, omalizumab targets IgE, and
dupilumab targets the IL-4 receptor alpha. All studies were RCTs and the
articles were published between 2011 and 2018.13–17
Study design
One of the 4 studies was a single center study;13 another involved two
centers in Belgium,14 while the other two were multicenter studies across
different countries (Table 1). Sample sizes ranged from 23 to 105 sub-
jects, with treatment groups ranging from 15 to 54, and controls ranging
from 8 to 51 participants. The mean age of eligible patients ranges from
47.4 to 51 years with a bilateral nasal polyp score of at least 5 (out of a
maximum score of 8) and at least a score of 2 for each nasal cavity despite
intranasal corticosteroid treatment. Patients with prior nasal surgery
were accepted. Asthma comorbidity is a major characteristic of this study
population, being present in 43%–100% of the patients; prespeciﬁed
enrollment goals were 50% of the patients with comorbid asthma in the
dupilumab study and 100% in the omalizumab study. Another important
patient characteristic is the history of previous endoscopic nasal surgery,
with 58%–100% of the participants reporting former surgery for
CRSwNP. In the latest mepolizumab study,16 severe recurrent bilateral
nasal polyposis was an important inclusion criterion, and all patients had
surgery/ies before the study inclusion. However, the number of previous
operations was not reported in all studies. As is known, asthma comor-
bidity and prior nasal surgery may increase the likelihood of a type 2
endotype,18 which might be decisive for the response to the bio-
therapeutics. The dosing and application schemes were tailored to the
biologics. In the 2 mepolizumab studies, the dosing regime was identical
(750 mg intravenous injection every 4 weeks), but the treatment periods
were different (8 weeks and 25 weeks), and in the latter study all par-
ticipants were treated with ﬂixonase aqueous nasal spray throughout the
treatment period. The omalizumab and dupilumab studies had the same
treatment period of 16 weeks with appropriate dosing regimens
(Table 1).
Total nasal endoscopic polyp score
The reduction in total nasal endoscopic polyp score (TPS) was the
most important indicator of efﬁcacy. It was assessed as the primary
outcome criterion in all compared studies (Table 2). In all 4 studies, the
TPS was signiﬁcantly reduced compared to baseline and also signiﬁcantly
different from controls. The decrease in TPS was most pronounced in the
omalizumab study (mean reduction at week 16, verum/placebo ¼ 2.67/
0.12). Dupilumab and the latest mepolizumab study had the same mean
value of TPS reduction in the treatment group (verum/placebo, 1.9 [95%
CI, 1.2 to 2.5]/0.3 [-0.4 to 1.0] for dupilumab at week 16 and 1.9 [SD
0.5]/0.7 [SD 0.5] for mepolizumab at week 25, respectively). In both
trials, intranasal corticosteroid spray was applied to all participants,
leading to slightly higher mean reductions in TPS in the control groups
than the other studies. Considering the treatment differences between
mepolizumab and placebo, the mean reduction of TPS in the two
mepolizumab studies were similar, although treatment periods (8 weeks
and 16 weeks separately) were different.
The improvement in TPS with omalizumab vs. placebo reached sta-
tistical signiﬁcance from week 8 onwards (after 2 or 4 doses) and in the
dupilumab study fromweek 4 (after 4 doses). Similarly, the mean change
from baseline in TPS reached signiﬁcance for mepolizumab vs. placebo
from week 8 (after 2 doses) in the ﬁrst13 and week 13 (after 3 doses) in
the latest mepolizumab study.16 Patients responding with an improve-
ment in TPS at week 8 were deﬁned as responders (n ¼ 12), accounting
for 60% in the ﬁrst mepolizumab study and stayed statistical signiﬁcance
till week 36 (8 months after the last dose). Other studies did not show
long-term data.
CT score
The changes in TPSs were also reﬂected in a redaction of polyp
burden in the sinuses as measured by CT scan (Table 2). Omalizumab and
dupilumab studies showed signiﬁcant Lund-Mackay score reductions
compared with controls (p < 0.001 vs. p ¼ 0.04). Dupilumab (plus
mometasone furoate) was more pronounced than with omalizumab
(mean reduction, 9.1 vs. 4.0). Unfortunately, the ﬁrst mepolizumab study
only reported that more than half of the mepolizumab-treated patients
and less than 20% of placebo group achieved an improvement in CT score
compared with baseline,13 with no deﬁnitive scores, and the latest
mepolizumab study did not provide any information of CT scan which
resulted in the inability to compare the two biotherapeutics.
Abbreviationns
IL Interleukin
IgE Immunoglobulin E
CRS Chronic rhinosinusitis
CRSwNP Chronic rhinosinusitis with nasal polyps
RCT Randomized controlled trial
GCS Glucocorticosteroid
INCS Intranasal corticosteroid spray
MFNS Mometasone furoate nasal spray
FANS Flixonase aqueous nasal spray
TPS Total nasal polyp score
CT Computed tomography
LOCF Last observation carried forwad
UPSIT University of Pennsylvania Smell Identiﬁcation Test
VAS Visual Analog Scale
SNOT-22 22-item SinoNasal Outcome Test
SF-36 Short-Form health questionnaire
RSOM-31 31-Item Rhinosinusitis Outcome Measuring Instrument
ACQ5 5-item Asthma Control Questionnaire
AQLQ Asthma Quality of Life Questionnaire
ESS Endoscopic sinus surgery
PnIF Peak nasal inspiratory ﬂow
FEV1 Forced expiratory volume in 1 second
ECP Eosinophil cationic protein
PARC Pulmonary and activation-regulated chemokine
MPO Myeloperoxidase
AEs Adverse events
L. Ren et al. World Allergy Organization Journal 12 (2019) 100050
2
Symptom scores and quality of life measures
Loss of smell, nasal congestion/obstruction, anterior rhinorrhea, and
postnasal drip/mucus in the throat are the main symptoms involved in
CRSwNP, and the data was generally available in the 4 studies, but the
methods used to assess them were different. The effect of dupilumab on
olfactory improvement was assessed by UPSIT (an objective measure-
ment ranging from 0 to 40, higher scores of 35–40 indicate normal sense
of smell), while the other 3 symptoms were captured using a categorical
scale (0 ¼ no symptoms, 1 ¼ mild symptoms, 2 ¼ moderate symptoms,
and 3 ¼ sever symptoms). The categorical scale was used to assess all 4
symptoms in the ﬁrst mepolizumab study and 3 symptoms (postnasal
drip was not reported) in the omalizumab study. However, the latest
mepolizumab study used a VAS scoring method and the results were
presented in centimeters (range 0–10). The variation in the scoring
methods hindered further comparison between different biologics.
Therefore, the effectiveness in symptom improvements of the mono-
clonal antibodies can only be judged from the treatment difference in a
single study (Table 2). Signiﬁcant improvements in nasal symptoms were
documented in all three studies (omalizumab, dupilumab, the latest
mepolizumab) except the ﬁrst mepolizumab study. The ﬁrst mepolizum
study has shown that the nasal symptoms were improved but did not
reach signiﬁcance although the TPS was signiﬁcantly reduced.13
Remarkably, the improvement in loss of smell in this study was reported
to stay at the same level during the whole period of follow-up (11 months
after the last dose), whereas the other symptoms normalized after a
period of time.
Quality of life scores are important clinical indicators for assessing
disease severity and are also important in the evaluation of the efﬁcacy of
biotherapeutics. Different scoring methods were designed in the four
studies (SNOT-22, UPISIT, SF-36, RSOM-31, AQLQ, ACQ5, et al.). Two
studies provided the SNOT-22 scores,15,16 and according to the outcome,
dupilumab was more effective than mepolizumab in reducing the
SNOT-22 total score (LS mean reduction, 18.1 [95% CI 10.6 to 25.6] vs
13.2 [95% CI 4.2 to 22.2]).
Nasal airﬂow (PnIF) and lung function (FEV1)
Additionally to symptom scores, PnIF and FEV1 are undoubtedly
objective clinical indicators. Dupilumab was reported to be effective in
Table 2
Clinical changes from baseline (verum versus placebo).
aMepolizumab13 Omalizumab14 Dupilumab15 Mepolizumab16
TPSs' mean reduction(SD) (verum/
placebo)
1.3 (1.72)/0.00 (1.72)，
p ¼ 0.028
2.67 (p ¼ 0.001)/0.12 (p ¼ 0.99) 1.9 (1.2–2.5)/0.3 (0.4–1.0) (LS
mean, 95% CI), p < 0.001
1.9 (1.4–2.4)/0.7(0.2–1.2) (LS
mean, 95%CI)b, p " 0.05
Lund-Mackay CT scan score mean
reduction (verum/placebo)
Any improvement: 10/2
patients
4.0 (p ¼ 0.02)/-0.5 (p ¼ 0.10) 9.1/0.2 (LS mean) (p < 0.001) NR
SNOT-22 score reduction (verum-
placebo)
NR NR 18.1 (10.6–25.6) (LS mean, 95%
CI), (p < 0.001)
13.2 (4.2–22.2) (LS mean, 95%
CI), (p ¼ 0.005)
UPSIT or loss of smell symptom
score
Improved (Not
signiﬁcant)
Improved (p ¼ 0.004) Improved (p < 0.001) Improved (p < 0.001)
Nasal congestion or obstruction Improved (Not
signiﬁcant)
Improved (p ¼ 0.002) Improved (p < 0.001) Improved (p ¼ 0.002)
Anterior rhinorrhea No improvement Improved (p¼ 0.003) Improved (AM, p < 0.0001; PM,
p ¼ 0.0008)
Improved (p < 0.001)
Postnasal drip or mucus in the
throat
Improved (not
signiﬁcant)
NR Improved (AM, p ¼ 0.002) Improved (p < 0.001)
SF-36 NR Physical health score Improved
(p¼ 0.02)
NR NR
RSOM-31 NR Sleep improved (p ¼ 0.03), general
symptoms improved (p ¼ 0.01).
NR NR
AQLQ or ACQ5 reduction NR AQLQ Improved (p ¼ 0.003) ACQ5 Improved (p < 0.001) NR
PnIF improvement (verum-placebo)
L/min
Improved (not
signiﬁcant)
NR 33.1 (12.7–53.5), (LS mean, 95%
CI) (p ¼ 0.002)
26.7 (3.1–50.2) (LS mean, 95%
CI) (p ¼ 0.027)
FEV1% predicted (verum/placebo) NR NR 1.9/9.0, (LS mean) (p ¼ 0.04) FEV1 (L), not signiﬁcant
TPS, total nasal endoscopic polyp score; LS, least squares; CI, conﬁdence interval; NR, not reported; SNOT-22, Sino-nasal Outcome Test; UPSIT, University of Penn-
sylvania Smell Identiﬁcation Test; SF-36, 36-Item Short Form Survey; RSOM-31, 31-Item Rhinosinusitis Outcome Measuring Instrument; AQLQ, Asthma Quality of Life
Questionnaire; ACQ5, 5-item Asthma Control Questionnaire; PnIF, Peak Nasal Inspiratory Flow; FEV1, forced expiratory volume 1. NR, not reported.
a Because of the dropouts, the shown data of this study were all last-observation-carried-forward imputation (LOCF) results.
b The TPSs were conversed from the corresponding ﬁgure in published articles by using WebPlotDigitizer v4.1.
Table 1
Study design of RCTs in CRSwNP.
aMepolizumab13 aOmalizumab14 aDupilumab15 aMepolizumab16
Published year 201113 201214 201615 201716
Target molecule IL-5 IgE IL-4 receptor alpha IL-5
Study design* Single center Two centers Multicenter (13 sites) Multicenter (6 sites)
NO. (verum/placebo) 30 (20/10) 23 (15/8) 60 (30/30) 105 (54/51)
Asthma % (verum/
placebo)
43% (50%/30%) 100% (100%/100%) 58% (63%/53%) 78% (81%/75%)
Former surgery %
(verum/placebo)
77% (75%/80%) 83% (87%/75%) 58% (63%/53%) 100% (100%/100%)
INCS medication – – MF FA
Dosing, application 750mg/4weeks # 2
(Intravenous)
According to tIgE levels and body weight, 375 mg max, every 2
weeks or every 4 weeks (subcutaneous)
600/300 mg/week
(Subcutaneous)
750mg/4weeks # 6
(Intravenous)
End point and last visit
(weeks)
8w/48w 16w/20w 16w/16w 25w/25w
a All these studies were randomized, double-blind, placebo-controlled studies. INCS, intranasal corticosteroid spray; NR, not reported; MF, Mometasone Furoate nasal
spray; FA, Flixonase Aqueous nasal spray; tIgE, total serum immunoglobulin E.
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improving PnIF and FEV1, and was superior to mepolizumab which did
not reach statistical signiﬁcance in improving FEV1. Mepolizumab13 did
not yield a statistically signiﬁcant beneﬁt concerning the PnIF volume (p
¼ 0.10), which was in contrast to subsequent research, possibly due to
the different treatment duration of 8 vs. 25 weeks.
Biomarkers
Patients with CRSwNP with comorbid asthma and/or former sur-
geries with disease recurrence likely express type 2 inﬂammation.10,19
The currently developed biologics based on type 2 cytokines and their
downstream products, including anti-IL-5, anti-IL-4, anti-IL-13 and
anti-IgE, are targeted at CRSwNP patients. Other cytokines like IL-33 and
thymic stromal lymphopoietin are also produced in patients with
CRSwNP19 and are potential therapeutic targets for this disease. How-
ever, no biomarkers are currently known to select between these possible
strategies. No difference in the baseline characteristics was found in the
responders vs. the non-responders in the mepolizumab-treated group. In
particular, no difference was found for IL-5 levels and blood eosinophil
counts. Omalizumab worked comparably in non-allergic compared with
allergic CRSwNP patients. Mepolizumab, blocking IL-5, reduced blood
eosinophil count, ECP and IL-5Rα in serum and several biomarkers
(IL-1β, IL-5Rα, IL-6 and MPO) in nasal secretions signiﬁcantly.13,16
Omalizumab, blocking IgE by complexing the molecules and reducing
free IgE, didn't induce any signiﬁcant changes in the serum and nasal
secretion parameters by treatment.14 In CRSwNP patients, tissue IgE
levels were reported to relate to the severity of disease, the presence of
comorbid asthma, and the presence of IgE to Staphylococcus aureus en-
terotoxins, while being independent of total serum IgE levels or allergy
skin prick test responses.20–22 Until now, only in the dupilumab study
data on biomarkers in nasal polyp tissue was reported.17 Dupilumab
reduced tissue ECP, pulmonary and activation-regulated chemokine
(PARC) and eotaxin-1 signiﬁcantly compared with placebo in polyp tis-
sue, total IgE and Eotaxin-3 in nasal secretions, and plasma eotaxin-3,
serum total IgE and eosinophils in the circulation.15,17 This demon-
strated that dupilumab targets a spectrum of type-2 inﬂammatory
markers at organ and systemic levels (Table 3).
Safety and adverse events
A variety of adverse events (AEs) were reported by the 4 RCTs, and
most of them were expected, with the most common AEs related to upper
airway infections (common cold, nasopharyngitis and headache). Eight
serious adverse events were reported in total, of which 3 patients in the
treatment group (1 patient treated with mepolizumab reported diver-
ticulitis, 2 patients treated with dupilumab reported herpes zoster,
arrhythmia and upper extremity pain or numbness). However, none of
the reported serious adverse events were deemed to relate to the bio-
therapeutics (Table 4). There were 4 reported serious adverse events in
the control group of the dupilumab study.
Discussion
Chronic Rhinosinusitis with nasal polyps (CRSwNP) is an often severe
persistent airway disease, which in Europe and the US is mainly char-
acterized by a type-2 inﬂammatory reaction. In spite of current treatment
recommendations such as topical GCS twice daily, recurrences after oral
GCS or surgeries are frequently observed. About one-third of the patients
with CRSwNP are considered control failures with the current treatment
options. This indicates a clear unmet need to search for other treatment
possibilities, which need to be structured in adequate diagnosis and
treatment care pathways.23
It is possible that better surgical techniques such as the “reboot
technique”, aiming to remove all inﬂamed mucosa of the sinuses, but
leaving nasal mucosa untouched, would change this situation.24 The
nasal epithelium covers the sinuses after just 4–6 weeks and forms a
smooth ciliated epithelial barrier with goblet cells. No additional com-
plications have been observed with this technique in comparison to the
current standard, but signiﬁcantly reduced recurrence rates could be
demonstrated over 30 months post-operatively. However, this technique
is time demanding and asks special skills from the surgeon, and it has not
found broad acceptance yet. Furthermore, type 2 inﬂammatory nasal
polyps are frequently characterized by asthma comorbidity, which will
not be controlled by surgery.
Our group, therefore, have performed several proof-of-concept studies
in Ghent since 2005, starting with several investigator-initiated studies; we
Table 3
Comparison of mean changes from baseline in biomarkers between treatment and control groups.
aMepolizumab13 Omalizumab14 bDupilumab15,17 Mepolizumab16
Blood Eosinophils Reduced (p < 0.001) NR Not signiﬁcant (Temporary increase
in some patients)
Reduced (Baseline mean 500 cells/ml
drop to 50 cells/ml EoT)
Plasma eotaxin-3 NR NR Reduced (p < 0.001) NR
Serum Total IgE NR Complex Reduced (p < 0.001) NR
ECP Reduced (p ¼ 0.022) NR NR NR
IL-5Rα Reduced (p < 0.001) NR NR NR
TARC NR NR Not signiﬁcant NR
Nasal Secretions Total IgE Not signiﬁcant NR Reduced (p < 0.05) NR
ECP Not signiﬁcant NR Not signiﬁcant NR
IL-1β Reduced (p ¼ 0.043) NR NR NR
IL-5 Not signiﬁcant NR NR NR
IL-5Rα Reduced (p ¼ 0.010) NR NR NR
IL-6 Reduced (p ¼ 0.020) NR NR NR
MPO Reduced (p ¼ 0.009) NR NR NR
Eotaxin-3 NR NR Reduced (p < 0.001) NR
Nasal polyp tissue Total IgE NR NR Reduced (not signiﬁcant) NR
IL-13 NR NR Reduced (not signiﬁcant) NR
ECP NR NR Reduced (p < 0.01) NR
PARC NR NR Reduced (p < 0.01) NR
Eotaxin-1 NR NR Reduced (p < 0.05) (Not signiﬁcant
from baseline)
NR
Eotaxin-2 NR NR Reduced (not signiﬁcant) NR
Eotaxin-3 NR NR Reduced (not signiﬁcant) NR
ECP, eosinophil cationic protein; NR, non reported; IL, interleukin; IL-5R α, IL-5 receptor α subunit; TARC，Thymus and Activation-Regulated Chemokine; PARK,
pulmonary and activation-regulated chemokine; IL-1β, IL-1β subunit; MPO, myeloperoxidase. NR, not reported.
a Because of the dropouts, the shown data of this study were all last-observation-carried-forward imputation (LOCF) results.
b The nasal polyp biopsies were collected with 12 patients at baseline and Week 16 (n ¼ 4 placebo, n ¼ 8 dupilumab). Ref 17 covers the nasal biomarker data of the
clinical study presented in ref 15.
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demonstrated the effect of a monoclonal antibody to IL-5, reslizumab, on
the polyp score and symptoms, showing that in principle biologics could
work inCRSwNP.12 The hypothesis on the role of this antibodywas derived
from a former study in 1997 showing that IL-5 protein is increased in nasal
polyps and that this cytokine correlates to eosinophil presence.25 We also
showed in the sameyear that nasal polyp eosinophils in tissue have a longer
survival time compared to blood eosinophils and that anti-IL-5, but not
anti-IL-3 or anti-GM-CSF could induce apoptosis in tissue eosinophils,26
being conﬁrmed in human disease today. Further studies on the regulation
of the IL-5 receptor on eosinophils, describing transmembrane and soluble
receptors in polyps,27 will help to appreciate treatment effects of benrali-
zumab, an IL-5 receptor antagonist currently in Phase 3 trials.
Work on IgE in nasal polyps, speciﬁcally on Staphylococcus aureus
enterotoxin-speciﬁc IgE (SE-IgE) pointed to the role of IgE28; in the mean-
while it was demonstrated that anti-IgE (omalizumab) can successfully be
used in allergic as well as non-allergic type-2 inﬂammatory polyps.14
Finally, in a cluster analysis of biomarkers in CRS enabling an endotyping
approach to CRS,10 we demonstrated the differentiation of CRSwNP in
non-type 2, moderate and severe type 2 subgroups. A ﬁrst trial with dupi-
lumab, an anti-IL-4 receptor alpha antagonist blocking IL-4 and IL-13 ac-
tivities,15 showed that a broader impact on type 2 immune reactions does
lead to the reduction of IgE aswell as of local mucosal eosinophil migration
from the blood and activation,17 resulting in an even more pronounced
effect on nasal polyps, smell, quality of life and asthma comorbidity.
The studies discussed here are proof-of-concept trials with relatively
small patient numbers and limited observation time, largely based on the
nasal polyp score (TPS); the TPS is stable over time under placebo
treatment—in clear contract to symptom scores or quality of life ques-
tionnaires, showing placebo effects – and allows the differentiation of
verum vs. placebo with small subject numbers. Interestingly, all biologics
result in a reduction of the TPS by about 2 score points, representing a
clinical meaningful reduction equal to a two weeks oral GCS course. Still,
small differences in the results suggest a small superior effect for dupi-
lumab with respect to asthma control, smell, CT scan scores and SNOT-22
questionnaire.15
As demonstrated, CRSwNP in approximately 85% represents a type 2
inﬂammation (10); additionally, in these studies, 43–100% of the pa-
tients suffered from comorbid asthma, 58–100% had at least one former
surgery, and all patients had a polyp score of minimum 5 out of 8. Thus,
patients included into these studies showed type 2 inﬂammation in
probably 90–100% of subjects. As a consequence, serum IgE and blood
eosinophil counts were above normal limits for most patients, but not all,
in the studies in which those parameters were monitored. However, we
did not select patients based on biomarkers, as no biomarkers have been
established for individual CRSwNP patients, and no restrictions in the
application of the monoclonal antibodies are identiﬁed so far. However,
patients not showing a type 2 immune reaction are expected not to
respond to the treatment.
In evaluating these small studies, however, one has to appreciate that
the populations were different in terms of asthma comorbidity, probably
also in severity of type 2 inﬂammation, and treatment duration. There-
fore, we need to await Phase 3 studies, currently run and evaluated, to
decide on evidence-based care pathways, selection criteria as well as
stopping rules.18 Also in terms of safety, although biologics were well
tolerated in the small studies, more robust data will be available with the
Phase 3 trials being published (see Box).
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Box
Remaining questions
Which cells and mediators are crucial to target in order to optimize
the approach with biologics?
Are there subgroups within the type 2 positive subjects, asking for a
differentiation of therapy with different biologics?
Which clinical and biological markers would help to select the right
therapy for a given patient?
Which stopping rules apply for the different biologics in order to
avoid ineffective treatment?
What will be the role of biologics in care pathways for CRSwNP
treatment, speciﬁcally in comparison to systemic GCS and surgery?
Table 4
Adverse events reported in the biologics studies.
Mepolizumab13 Omalizumab14 Dupilumab15 Mepolizumab16
Total number of adverse events
No. (%) of patients, verum/placebo
Events, 21/3
N (%) of all patients, 16 (53%)
Events, 24/8 30 (100%)/25 (83%) 40 (75%)/42 (81%)
Most frequent adverse events
% Of the patients, verum/placebo
Common cold (25%/10%)
Bronchitis (15%/0%)
Sinusitis (10%/10%)
Short of breath (5%/0%)
Headache (5%/0%)
Common cold (53%/0%)
Frontal headache (27%/13%)
Nasal obstruction (20%/20%)
Shortness of breath (13%/13%)
Otitis media (13%/0%)
Nasopharyngitis (47%/33%)
Injection-site reaction (40%/7%)
Oropharyngeal pain (23%/7%)
Epistaxis (23%/7%)
Headache (20%/17%)
Headache (25%/38%)
Nasopharyngitis (19%/23%)
Oropharyngeal pain (11%/8%)
Back pain (9%/0%)
Inﬂuenza (8%/4%)
Serious adverse events, verum/placebo a1/0 None a3/4 None
a The serious adverse event was not considered to be related to the study drug.
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